Effect of fluoxetine on tolerance to the analgesic effect of morphine in mice with skin cancer

Pharmacological Reports

Volumn 61, Issue 3, 2009, Pages 453-458

  Nayebi, Alireza Mohajjel ^a,b   Rezazadeh, Hassan ^b   Parsa, Yousef ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Fluoxetine; Morphine; Skin cancer; Tolerance

Indexed keywords

CROTON OIL; DIMETHYLBENZ[A]ANTHRACENE; FLUOXETINE; MORPHINE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PAIN; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERANCE; FEMALE; HOT PLATE TEST; LATENT PERIOD; MOUSE; NONHUMAN; PAIN THRESHOLD; SKIN CANCER; TREATMENT DURATION; TREATMENT RESPONSE;

ANALGESICS, OPIOID; ANIMALS; DRUG INTERACTIONS; DRUG TOLERANCE; FEMALE; FLUOXETINE; MICE; MORPHINE; PAIN; PAIN THRESHOLD; SEROTONIN UPTAKE INHIBITORS; SKIN NEOPLASMS;

EID: 67651174418     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70086-6     Document Type: Article

References (41)

1. Abdel-Zaher AO, Hamdy MM, Aly SA, Abdel-Hady RH, Abdel-Rahman S: Attenuation of morphine tolerance and dependence by aminoguanidine in mice. Eur J Pharmacol, 2006, 540, 60-66.
2. Arends RH, Hayashi TG, Luger TJ, Shen DD: Co-treatment with racemic fenfluramine inhibits the development of tolerance to morphine analgesia in rats. J Pharmacol Exp Ther, 1998, 286, 585-592.
3. Ashman LK, Murray AW, Cook MG, Kotlarski I: Two-stage skin carcinogenesis in sensitive and resistant mouse strains. Carcinogenesis, 1982, 3, 99-102.
4. Bryant CD, Eitan S, Sinchak K, Fanselow MS, Evans CJ: NMDA receptor antagonism disrupts the development of morphine analgesic tolerance in male, but not female C57BL/6J mice. Am J Physiol Regul Integr Comp Physiol, 2006, 291, R315-326.
5. Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, Brummett C, Mao J: The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med, 2008, 33, 199-206.
6. Danysz W, Kozela E, Parsons CG, Sladek M, Bauer T, Popik P: Peripherally acting NMDA receptor/glycineB site receptor antagonists inhibit morphine tolerance. Neuropharmacology, 2005, 48, 360-371.
7. Davis MP, Walsh D, Lagman R, LeGrand SB: Controversies in pharmacotherapy of pain management. Lancet Oncol, 2005, 6, 696-704.
8. Drouin C, Blanc G, Trovero F, Glowinski J, Tassin JP: Cortical I-adrenergic regulation of acute and sensitized morphine locomotor effects. Neuroreport, 2001, 12, 3483-3486.
9. Dyuizen IV, Deridovich II, Kurbatskii RA, Shorin VV: No-ergic neurons of the cervical nucleus of the rat brain in normal conditions and after administration of opiates. Neurosci Behav Physiol, 2004, 34, 621-626.
10. Fang LH, Zhang YH, Ku BS: Fangchinoline inhibited the antinociceptive effect of morphine in mice. Phytomedicine, 2005, 12, 183-188.
11. Fortier MA, Krishnaswamy K, Danyod G, Boucher-Kovalik S, Chapdalaine P: A postgenomic integrated view of prostaglandins in reproduction: implication of other body systems. Curr Med Chem, 2008, 15, 2866-2875.
12. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S et al.: Expert Working Group of the Research Network of the European Association for Palliative Care: Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer, 2001, 84, 587-593.
13. Jolas T, Aghajanian GK: Opioids suppress spontaneous and NMDA-induced inhibitory postsynaptic currents in the dorsal raphe nucleus of the rat in vitro. Brain Res, 1997, 755, 229-245.
14. Jolas T, Nestler EJ, Aghajanian GK: Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway. Neuroscience, 2000, 95, 433-443.
15. 2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phophorylation. Psychopharmacology (Berl), 2008, 201, 443-458.
16. Litt W, Wang CH, Cui Y, Mo LQ, Zhi JL, Sun SN, Wang Y et al.: Inhibition of neuronal nitric oxide synthase antagonizes morphine antinociceptive tolerance by decreasing activation of p38 MAPK in the spinal microglia. Neurosci Lett, 2006, 410, 174-177.
17. Mandalà M, Moro C, Labianca R, Cremonesi M, Barni S: Optimizing use of opiates in the management of cancer pain. Ther Clin Risk Manag, 2006, 2, 447-453.
18. Manev R, Uz T, Manev H: Fluoxetine increase the content of neurotrophic protein S1000beta in the rat hippocampus. Eur J Pharmacol, 2001, 420, R1-2
19. Matsuzawa-Yanagida K, Narita M, Nakajima M, Kuzumaki N, Niikura K, Nozaki H, Takagi T et al.: Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. Neuropsychopharmacology, 2008, 33, 1952-1965.
20. Mendez IA, Trujillo KA: NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats. Psychopharmacology, 2008, 196, 497-509.
21. Narita M, Suzuki M, Narita M, Yajima Y, Suzuki R, Shioda S, Suzuki T: Neuronal protein kinase C gamma-dependent proliferation and hypertrophy of spinal cord astrocytes following repeated in vivo administration of morphine. Eur J Neurosci, 2004, 19, 479-484.
22. 2 receptors of dorsal and median raphe nucleus in tolerance to morphine analgesia in rats. Pharmacol Biochem Behav, 2006, 83, 203-207.
23. Nayebi ARM, Hassanpour M, Rezazadeh H: Effect of chronic and acute administration of fluoxetine and its additive effect with morphine on the behavioural responses in the formalin test in rats. J Pharm Pharmacol, 2001, 53, 219-225.
24. Nemmani KV, Mogil JS: Serotonin-GABA interactions in the modulation of mu- and kappa-opioid analgesia. Neuropharmacology, 2003, 44, 304-310.
25. O'Connell JF, Klein-Szanto AJ, DiGiovanni DM, Fries JW, Slaga TJ: Enhanced malignant progression of mouse skin tumors by the free-radical generator benzoyl peroxide. Cancer Res, 1986, 46, 2863-2865.
26. Passik SD, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Edgerton S, Dugan W: Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients. A demonstration project. J Pain Symptom Manage, 2002, 24, 318-327.
27. Rezazadeh H, Nayebi AR, Garjani A, Sheikhulislami A, Babaei H: Evidence that iron overload plus croton oil induce skin tumours in mice. Hum Exp Toxicol, 2005, 24, 409-413.
28. Santamarta MT, Ulibarri I, Pineda J: Inhibition of neuronal nitric oxide synthase attenuates the development of morphine tolerance in rats. Synapse, 2005, 57, 38-46.
29. Schäfers M, Sorkin L: Effect of cytokines on neuronal excitability. Neurosci Lett, 2008, 437, 188-193.
30. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain, 1999, 83, 389-400.
31. Song P, Zhao ZQ: The involvement of glial cells in the development of morphine tolerance. Neurosci Res, 2001, 39, 281-286.
32. Sounvoravong S, Nakashima MN, Wada M, Nakashima K: Modification of antiallodynic and antinociceptive effects of morphine by peripheral and central action of fluoxetine in neuropathic mice model. Acta Biol Hung, 2007, 58, 369-379.
33. Strong V, Waters R, Hibberd C, Murray G, Wall L, Walker J, McHugh G et al.: Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet, 2008, 372, 40-48.
34. Tramontina AC, Tramontina F, Bobermin LD, Zanotto C, Souza DF, Leite MC, Nardin P et al.: Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32, 1580-1583.
35. Trujillo KA, Akil H: Excitatory amino acids and drugs of abuse: a role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug Alcohol Depend, 1995, 38, 139-154.
36. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K: Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia, 2004, 45, 89-95.
37. Wacnik PW, Kehl LJ, Trempe TM, Ramnaraine ML, Beitz AJ, Wilcox GL: Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain, 2003, 101, 175-186.
38. Woolf CJ, Salter MW: Neuronal plasticity: increasing the gain in pain. Science, 2000, 288, 1765-1769.
39. Xu T, Jiang W, Du D, Xu Y, Hu Q, Shen Q: Role of spinal metabotropic glutamate receptor subtype 5 in the development of tolerance to morphine-induced antinociception in rat. Neurosci Lett, 2007, 420, 155-159.
40. Xu T, Jiang W, Du D, Xu Y, Zhou Q, Pan X, Lou Y et al.: Inhibition of MPEP on the development of morphine antinociceptive tolerance and the biosynthesis of neuronal nitric oxide synthase in rat spinal cord. Neurosci Lett, 2008, 436, 214-218.
41. Zhao ZQ, Chiechio S, Sun YG, Zhang KH, Zhao CS, Scott M, Johnson RL et al.: Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci, 2007, 27, 6045-6053.